» Articles » PMID: 34068767

The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review

Overview
Journal Cells
Publisher MDPI
Date 2021 Jun 2
PMID 34068767
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Asparagine endopeptidase (AEP), also called legumain, is currently the only known cysteine protease that specifically cleaves peptide bonds in asparaginyl residue in the mammalian genome. Since 2003, AEP has been reported to be widely expressed in a variety of carcinomas and is considered a potential therapeutic target. In the following years, researchers intensively investigated the substrates of AEP and the mechanism of AEP in partial tumors. With the identification of substrate proteins such as P53, integrin αvβ3, MMP-2, and MMP-9, the biochemical mechanism of AEP in carcinomas is also more precise. This review will clarify the probable mechanisms of AEP in the progression of breast carcinoma, glioblastoma, gastric carcinoma, and epithelial ovarian carcinoma. This review will also discuss the feasibility of targeted therapy with AEP inhibitor (AEPI) in these carcinomas.

Citing Articles

Radiotherapy resistance driven by Asparagine endopeptidase through ATR pathway modulation in breast cancer.

Morillo-Huesca M, G Lopez-Cepero I, Conesa-Bakkali R, Tome M, Watts C, Huertas P J Exp Clin Cancer Res. 2025; 44(1):74.

PMID: 40012043 PMC: 11866873. DOI: 10.1186/s13046-025-03334-6.


HIF2α drives ccRCC metastasis through transcriptional activation of methylation-controlled J protein and enhanced prolegumain secretion.

Shen T, Su Y, Wang D, Li G, Liu X, Sun C Cell Death Dis. 2025; 16(1):93.

PMID: 39948060 PMC: 11825665. DOI: 10.1038/s41419-025-07432-3.


Non-Canonical, Extralysosomal Activities of Lysosomal Peptidases in Physiological and Pathological Conditions: New Clinical Opportunities for Cancer Therapy.

Conesa-Bakkali R, Morillo-Huesca M, Martinez-Fabregas J Cells. 2025; 14(2).

PMID: 39851495 PMC: 11763575. DOI: 10.3390/cells14020068.


Secretase promotes AD progression: simultaneously cleave Notch and APP.

Yang K, Zhang J, Feng M, Yao K, Liu Y, Zhou M Front Aging Neurosci. 2024; 16:1445470.

PMID: 39634655 PMC: 11615878. DOI: 10.3389/fnagi.2024.1445470.


Legumain in cardiovascular diseases.

Zhou L, Wu J, Wei Z, Zheng Y Exp Biol Med (Maywood). 2024; 249:10121.

PMID: 39104790 PMC: 11298360. DOI: 10.3389/ebm.2024.10121.


References
1.
Chen J, Fortunato M, Barrett A . Activation of human prolegumain by cleavage at a C-terminal asparagine residue. Biochem J. 2000; 352 Pt 2:327-34. PMC: 1221463. View

2.
Ni J, Abrahamson M, Zhang M, Fernandez M, Grubb A, Su J . Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem. 1997; 272(16):10853-8. DOI: 10.1074/jbc.272.16.10853. View

3.
Zhou W, Fong M, Min Y, Somlo G, Liu L, Palomares M . Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-15. PMC: 4016197. DOI: 10.1016/j.ccr.2014.03.007. View

4.
Srikanth M, Kessler J . Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol. 2012; 8(6):307-18. PMC: 3773927. DOI: 10.1038/nrneurol.2012.76. View

5.
Alvarez-Fernandez M, Barrett A, Gerhartz B, Dando P, Ni J, Abrahamson M . Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem. 1999; 274(27):19195-203. DOI: 10.1074/jbc.274.27.19195. View